1. Home
  2. IMRN vs DCM Comparison

IMRN vs DCM Comparison

Compare IMRN & DCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

SELL

Current Price

$0.88

Market Cap

7.7M

Sector

Health Care

ML Signal

SELL

Logo DeFi Capital Markets Inc. Common Stock

DCM

DeFi Capital Markets Inc. Common Stock

N/A

Current Price

$3.16

Market Cap

9.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMRN
DCM
Founded
1994
1969
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Electronic Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
9.1M
IPO Year
2016
2025

Fundamental Metrics

Financial Performance
Metric
IMRN
DCM
Price
$0.88
$3.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 13.4K
7.0K
Earning Date
08-28-2026
01-30-2018
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,847,163.00
Revenue This Year
$12.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.68
$2.82
52 Week High
$1.99
$4.51

Technical Indicators

Market Signals
Indicator
IMRN
DCM
Relative Strength Index (RSI) 34.56 33.40
Support Level $0.75 N/A
Resistance Level $0.89 $3.45
Average True Range (ATR) 0.07 0.28
MACD 0.00 0.00
Stochastic Oscillator 22.05 0.00

Price Performance

Historical Comparison
IMRN
DCM

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

About DCM DeFi Capital Markets Inc. Common Stock

DeFi Capital Markets Inc is a digital asset and financial technology company focused on tokenization, proprietary quantitative trading, digital asset market making, blockchain infrastructure and investments in digital and tokenized assets. Through its subsidiaries and strategic investments, the Company intends to participate directly in the ongoing convergence of traditional capital markets, blockchain technology and decentralized finance.

Share on Social Networks: